Imatinib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Imatinib

Examples of brand names: Glivec [EU/DE]

ATC code: L01EA01

Main use (for orientation): CML; GIST

Documented research summary

Two preclinical CBD/imatinib combination papers recorded. No clinical pharmacokinetic interaction demonstrated; a laboratory antitumour effect is not a treatment recommendation.

Uncertainties and limitations

Single-ingredient oral imatinib preparation for human use, mesylate salt.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0178

Type of result: Preclinical evidence

Observation: Synergistic antiproliferative effect of CBD and imatinib in CML cells.

Mechanism: TRPV2/mitophagy and cellular differentiation

Study type: Cell and, where applicable, animal experiment; abstract assessed

Context studied: CML cell models, including imatinib-resistant cells; no patient pharmacokinetics.

Clinical interpretation: Experimental finding; no clinical treatment or dose recommendation

Limitations and uncertainties: Abstract-based; concentrations and combination effect sizes not extracted from the full text. A formal erratum (PMID37221079, 2023) replaces Figure 1B; consider the corrected presentation. This erratum is not a retraction notice.

Original sources for this finding: The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib. [BMED34971020]; Correction: The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib [AUDIT_B_CORR_37221079]

CBD – laboratory and animal studies

Finding ID: B0179

Type of result: Preclinical evidence

Observation: CBD plus imatinib enhanced apoptosis/differentiation-related signals in sensitive K-562S cells; resistant K-562R cells showed only partial restoration.

Mechanism: Exosomal miRNA signalling pathways

Study type: Cell and, where applicable, animal experiment; abstract assessed

Context studied: In-vitro transcriptomics/miRNA, not clinical evidence concerning resistance.

Clinical interpretation: Experimental finding; no clinical treatment or dose recommendation

Limitations and uncertainties: Biomarker/cell finding; no evidence of improved patient prognosis.

Original sources for this finding: Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia. [BMED41657764]

References and access status

[V2_LABEL_D0367] IMATINIB MESYLATE (IMATINIB) TABLET, FILM COATED [GOLDEN STATE MEDICAL SUPPLY, INC.]

Original source / bibliographic reference

Authors: Golden State Medical Supply, Inc.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED41657764] Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia.

Original source / bibliographic reference

Authors: Donchev PP, Vasileva EY, Paunova-Krasteva TS, Danova ST.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.gmg.2026.100094

PMID: 41657764

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED34971020] The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.

Original source / bibliographic reference

Authors: Maggi F, Morelli MB, Tomassoni D, Marinelli O, Aguzzi C, Zeppa L, Nabissi M, Santoni G, Amantini C.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.1111/cas.15257

PMID: 34971020

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[AUDIT_B_CORR_37221079] Correction: The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib

Original source / bibliographic reference

Authors: Correction has no separately listed authors in PubMed; corrects Maggi et al.

Year: 2023

Source type: Published Erratum

DOI: 10.1111/cas.15825

PMID: 37221079

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility